XTX Topco Ltd Grows Stock Holdings in Geron Co. (NASDAQ:GERN)

XTX Topco Ltd raised its stake in shares of Geron Co. (NASDAQ:GERN) by 1,923.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 220,844 shares of the biopharmaceutical company’s stock after acquiring an additional 209,929 shares during the period. XTX Topco Ltd’s holdings in Geron were worth $782,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new stake in shares of Geron during the fourth quarter worth approximately $28,000. Rovin Capital UT ADV boosted its holdings in shares of Geron by 26.9% in the fourth quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 3,660 shares in the last quarter. Monterey Private Wealth Inc. acquired a new position in shares of Geron during the fourth quarter worth about $63,000. Paces Ferry Wealth Advisors LLC purchased a new position in Geron during the fourth quarter worth about $83,000. Finally, Polymer Capital Management US LLC acquired a new stake in Geron in the fourth quarter valued at about $85,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Price Performance

Shares of NASDAQ:GERN opened at $1.27 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The business’s fifty day moving average price is $1.79 and its two-hundred day moving average price is $3.05. The stock has a market cap of $808.88 million, a PE ratio of -3.97 and a beta of 0.66. Geron Co. has a one year low of $1.17 and a one year high of $5.34.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. On average, analysts forecast that Geron Co. will post -0.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. HC Wainwright reissued a “neutral” rating on shares of Geron in a research note on Wednesday, March 12th. Needham & Company LLC reissued a “buy” rating and issued a $5.00 target price on shares of Geron in a report on Wednesday, March 12th. Stifel Nicolaus decreased their target price on shares of Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Scotiabank cut their price target on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating for the company in a report on Thursday, February 27th. Finally, Barclays reissued an “overweight” rating and set a $4.00 price objective (down previously from $9.00) on shares of Geron in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $5.75.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.